115 related articles for article (PubMed ID: 32631391)
1. Dysregulation of cancer genes by recurrent intergenic fusions.
Yun JW; Yang L; Park HY; Lee CW; Cha H; Shin HT; Noh KW; Choi YL; Park WY; Park PJ
Genome Biol; 2020 Jul; 21(1):166. PubMed ID: 32631391
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis Reveals the Diverse Landscape of Novel Sense and Antisense Fusion Transcripts.
Vellichirammal NN; Albahrani A; Banwait JK; Mishra NK; Li Y; Roychoudhury S; Kling MJ; Mirza S; Bhakat KK; Band V; Joshi SS; Guda C
Mol Ther Nucleic Acids; 2020 Mar; 19():1379-1398. PubMed ID: 32160708
[TBL] [Abstract][Full Text] [Related]
3. Drug repositioning in thyroid cancer: from point mutations to gene fusions.
Sánchez-Marín D; Silva-Cázares MB; González-Del Carmen M; Campos-Parra AD
Front Oncol; 2024; 14():1407511. PubMed ID: 38779099
[TBL] [Abstract][Full Text] [Related]
4. Discovery of A Polymorphic Gene Fusion via Bottom-Up Chimeric RNA Prediction.
Elfman J; Goins L; Heller T; Singh S; Wang YH; Li H
bioRxiv; 2023 Feb; ():. PubMed ID: 36778239
[TBL] [Abstract][Full Text] [Related]
5. Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer.
Qi T; Qu Q; Li G; Wang J; Zhu H; Yang Z; Sun Y; Lu Q; Qu J
Am J Cancer Res; 2020; 10(10):3083-3105. PubMed ID: 33163259
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis of Alternative Lengthening of Telomere Activity.
Sung JY; Lim HW; Joung JG; Park WY
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32784588
[TBL] [Abstract][Full Text] [Related]
7. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
[TBL] [Abstract][Full Text] [Related]
8. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
9. Germline Structural Variations in Cancer Predisposition Genes.
Pócza T; Grolmusz VK; Papp J; Butz H; Patócs A; Bozsik A
Front Genet; 2021; 12():634217. PubMed ID: 33936164
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive epigenome atlas reveals DNA methylation regulating skeletal muscle development.
Yang Y; Fan X; Yan J; Chen M; Zhu M; Tang Y; Liu S; Tang Z
Nucleic Acids Res; 2021 Feb; 49(3):1313-1329. PubMed ID: 33434283
[TBL] [Abstract][Full Text] [Related]
11. A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3.
Wang Q; Cheng B; Singh S; Tao Y; Xie Z; Qin F; Shi X; Xu J; Hu C; Tan W; Li H; Huang H
NPJ Precis Oncol; 2024 Jan; 8(1):11. PubMed ID: 38225404
[TBL] [Abstract][Full Text] [Related]
12. Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study.
Jiang A; Pang Q; Gan X; Wang A; Wu Z; Liu B; Luo P; Qu L; Wang L
Cancer Innov; 2022 Aug; 1(2):146-167. PubMed ID: 38090653
[TBL] [Abstract][Full Text] [Related]
13. HYENA detects oncogenes activated by distal enhancers in cancer.
Yu A; Yesilkanal AE; Thakur A; Wang F; Yang Y; Phillips W; Wu X; Muir A; He X; Spitz F; Yang L
bioRxiv; 2024 Apr; ():. PubMed ID: 38076958
[TBL] [Abstract][Full Text] [Related]
14. Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies.
Salokas K; Dashi G; Varjosalo M
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509339
[TBL] [Abstract][Full Text] [Related]
15. Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion.
He J; Yao Y; Quan F; Lu Z; Wang J; Gao W
Onco Targets Ther; 2023; 16():535-540. PubMed ID: 37441362
[TBL] [Abstract][Full Text] [Related]
16. Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS.
van Belzen IAEM; Cai C; van Tuil M; Badloe S; Strengman E; Janse A; Verwiel ETP; van der Leest DFM; Kester L; Molenaar JJ; Meijerink J; Drost J; Peng WC; Kerstens HHD; Tops BBJ; Holstege FCP; Kemmeren P; Hehir-Kwa JY
BMC Cancer; 2023 Jul; 23(1):618. PubMed ID: 37400763
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.
Li Q; Li Z; Luo T; Shi H
Mol Biomed; 2022 Dec; 3(1):47. PubMed ID: 36539659
[TBL] [Abstract][Full Text] [Related]
18. Novel gene-intergenic fusion involving ubiquitin E3 ligase UBE3C causes distal hereditary motor neuropathy.
Cutrupi AN; Narayanan RK; Perez-Siles G; Grosz BR; Lai K; Boyling A; Ellis M; Lin RCY; Neumann B; Mao D; Uesugi M; Nicholson GA; Vucic S; Saporta MA; Kennerson ML
Brain; 2023 Mar; 146(3):880-897. PubMed ID: 36380488
[TBL] [Abstract][Full Text] [Related]
19. Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with
Shin YJ; Yun JW; Kim HS
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289913
[TBL] [Abstract][Full Text] [Related]
20. The molecular understanding of super-enhancer dysregulation in cancer.
Yoshino S; Suzuki HI
Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
